An official website of the United States government Here's how you know

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

Biologic License Application (BLA): 125486
Company: GENENTECH

Office Director Memo

Summary Review

Products on BLA 125486

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
GAZYVA	OBINUTUZUMAB	1000MG/40ML	INJECTABLE;INJECTION	Prescription	None	No	No

Approval Date(s) and History, Letters, Labels, Reviews for BLA 125486

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
11/01/2013	ORIG-1	Approval		N/A; Orphan	Label (PDF) Letter (PDF) Review Summary Review (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125486s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/125486Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/125486Orig1s000TOC.cfm https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125486Orig1s000SumR.pdf

Supplements

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
10/17/2025	SUPPL-38	Supplement	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125486s037s038lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/125486Orig1s037,s038ltr.pdf
10/17/2025	SUPPL-37	Supplement	Label (PDF) Letter (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125486s037s038lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/125486Orig1s037,s038ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/125486Orig1s037,s038ltr.pdf
07/27/2022	SUPPL-34	Supplement	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125486s034lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/125486Orig1s034ltr.pdf
07/12/2022	SUPPL-33	Supplement	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125486s033lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/125486Orig1s033ltr.pdf
02/14/2022	SUPPL-29	Supplement	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125486s029lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/125486Orig1s029ltr.pdf
03/27/2020	SUPPL-25	Supplement	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125486s025lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/125486Orig1s025ltr.pdf
11/16/2017	SUPPL-18	Supplement	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125486s017s018lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/125486Orig1s017s018ltr.pdf
11/16/2017	SUPPL-17	Supplement	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125486s017s018lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/125486Orig1s017s018ltr.pdf
02/26/2016	SUPPL-13	Supplement	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125486s013lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/125486Orig1s013ltr.pdf
09/23/2015	SUPPL-10	Supplement	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125486s010lbledt.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/125486Orig1s010ltr.pdf
12/24/2014	SUPPL-9	Supplement	Letter (PDF)	Label is not available on this site.	https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/125486Orig1s009ltr.pdf
06/27/2014	SUPPL-8	Supplement	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125486_s008lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/125486Orig1s008ltr.pdf

Labels for BLA 125486

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
10/17/2025	SUPPL-38	Efficacy-Labeling Change With Clinical Data	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125486s037s038lbl.pdf
10/17/2025	SUPPL-37	Efficacy-New Indication	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125486s037s038lbl.pdf
07/27/2022	SUPPL-34	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125486s034lbl.pdf
07/12/2022	SUPPL-33	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125486s033lbl.pdf
02/14/2022	SUPPL-29	Efficacy-Labeling Change With Clinical Data	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125486s029lbl.pdf
03/27/2020	SUPPL-25	Efficacy-Labeling Change With Clinical Data	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125486s025lbl.pdf
11/16/2017	SUPPL-18	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125486s017s018lbl.pdf
11/16/2017	SUPPL-17	Efficacy-New Indication	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125486s017s018lbl.pdf
02/26/2016	SUPPL-13	Efficacy-Labeling Change With Clinical Data	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125486s013lbl.pdf
09/23/2015	SUPPL-10	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125486s010lbledt.pdf
06/27/2014	SUPPL-8	Labeling	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125486_s008lbl.pdf
11/01/2013	ORIG-1	Approval	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125486s000lbl.pdf

Top